Coalition for Epidemic Preparedness Innovations funding builds on Moderna&#39;s prior filovirus research and supports preclinical development and Phase 1 clinical evaluation CAMBRIDGE, MA / ACCESS Newswire / June 1, 2026 /

<p><i><strong>Coalition for Epidemic Preparedness Innovations</strong></i><strong> </strong><i><strong>funding builds on Moderna's prior filovirus research and supports preclinical development and Phase 1 clinical evaluation</strong></i></p> <p><strong id="dateline">CAMBRIDGE, MA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 1, 2026 / </strong>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MRNA">MRNA</a>) today announced an expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a potential vaccine against Bundibugyo ebolavirus (BDBV), a cause of Ebola virus disease for which there are currently no licensed vaccines indicated.</p><p>Under the agreement, CEPI has committed up to US $50 million to support preclinical development and Phase 1 clinical testing of Moderna's investigational BDBV vaccine candidate. The funding will also support parallel manufacturing activities, enabling doses to be produced while clinical evaluation is underway and positioning the program to rapidly advance into large-scale Phase 2/3 trials should the Phase 1 safety and immunogenicity data support further development.</p><p>The vaccine candidate is being developed using Moderna's mRNA platform, the same technology that demonstrated rapid development, scalability, and global deployment capabilities during the COVID-19 pandemic. The program also builds on Moderna's existing research and development efforts in filoviruses, including Ebola-related viruses.</p><p>The collaboration further expands Moderna's longstanding strategic collaboration with CEPI, which is focused on accelerating the development of vaccines and other countermeasures against epidemic and pandemic threats.</p><p>"At Moderna, we believe our mRNA platform can play an important role in responding rapidly to emerging infectious disease threats," said St&#233;phane Bancel, Chief Executive Officer of Moderna. "We are proud to expand our strategic collaboration with CEPI to advance a potential vaccine candidate against Bundibugyo ebolavirus, leveraging our established technology and experience in filovirus vaccine development. We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most."</p><p>By combining CEPI's funding and expertise in epidemic preparedness with Moderna's mRNA platform and manufacturing capabilities, the collaboration aims to accelerate the development of a potential vaccine that could help strengthen global readiness against future Ebola outbreaks.</p><p><strong>"</strong>With Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease," said Dr. Richard Hatchett, CEO of CEPI. "CEPI's urgent funding and support aims to advance safe, effective vaccines to help control this epidemic."</p><p>The current outbreak - declared a Public Health Emergency of International Concern (PHEIC) and a Public Health Emergency of Continental Security (PHECS) by the World Health Organization and Africa CDC, respectively - has already caused more than 900 suspected cases and more than 220 suspected deaths, making it the third largest Filovirus outbreak in history.</p><p><strong>About Moderna</strong></p><p>Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.</p><p>With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit <a rel="nofollow" href="https://pr.report/hn3n">modernatx.com</a> and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.</p><p><strong>Forward-Looking Statements</strong></p><p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's expanded collaboration with CEPI and CEPI's investment; the ability to rapidly advance into large-scale Phase 2/3 trials; the potential for a vaccine against BDBV. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at <a href="http://www.sec.gov" title="www.sec.gov">www.sec.gov</a>. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.</p><p><strong>Moderna Contacts</strong></p><p>Media:</p><p>Chris Ridley<br/>Vice President, Global Head of Communications<br/>+1 617-800-3651<br/><a rel="nofollow" href="mailto:Chris.Ridley@modernatx.com">Chris.Ridley@modernatx.com</a></p><p>Investors:</p><p>Lavina Talukdar<br/>Senior Vice President & Head of Investor Relations<br/>+1 617-209-5834<br/><a rel="nofollow" href="mailto:Lavina.Talukdar@modernatx.com">Lavina.Talukdar@modernatx.com</a></p><p><strong>SOURCE:</strong> Moderna, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/moderna-and-cepi-expand-strategic-collaboration-to-advance-potential-1172083'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1172083" width="0" height="0"/>

MRNA

Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus

Moderna, CEPI Expand Funding for Bundibugyo Ebola Vaccine Program

Moderna said on Monday it has partnered with the ​Coalition for Epidemic Preparedness Innovations ‌t...

Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Coalition for Epidemic Preparedness Innovations funding builds on Moderna&amp;#39;s prior filovirus research and supports preclinical development and Phase 1 clinical evaluation CAMBRIDGE, MA / ACCESS Newswire / June 1, 2026 /</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Moderna and CEPI expanded funding of up to $50 million to advance a Bundibugyo ebolavirus vaccine candidate using Moderna&#039;s mRNA platform, targeting preclinical and Phase 1 development with manufacturing parallelization. The collaboration aims to accelerate progression to Phase 2/3 if Phase 1 data are favorable, signaling continued government-backed support for mRNA vaccines in outbreak readiness.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>CEPI commits up to $50M for Moderna&#039;s BDBV vaccine; funds preclinical and Phase 1.</li><li>Funding enables parallel manufacturing to support trials and rapid scale if data positive.</li><li>Program leverages Moderna&#039;s mRNA platform and filovirus vaccine experience.</li><li>Outbreak: Bundibugyo virus with 900+ suspected cases and 220+ deaths.</li><li>CEPI collaboration aims to accelerate vaccine readiness against future Ebola outbreaks.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Moderna, Inc. (MRNA)</strong>: Expanded CEPI collaboration to fund BDBV vaccine; potential near-term pipeline upside and sentiment.</li><li><strong>Coalition for Epidemic Preparedness Innovations (CEPI)</strong>: Public health funding entity providing up to $50M; signals government-backed support for mRNA outbreak vaccines.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>Industry News: Highlights a public-private funding collaboration expanding Moderna&#039;s mRNA vaccine program, reinforcing the platform&#039;s role in outbreak preparedness and potential near-term sentiment improvement for MRNA.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>MRNA could see near-term stock reaction on funding and pipeline momentum.</li><li>Milestones over 12-18 months could reset valuation.</li><li>Parallel manufacturing funds may de-risk clinical timelines.</li><li>Outbreak severity and CEPI messaging supportive.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date: June 1, 2026.</li><li>CEPI committed up to $50 million.</li><li>Development scope: preclinical and Phase 1 for BDBV vaccine.</li><li>Manufacturing parallelization to enable large-scale Phase 2/3.</li><li>Outbreak metrics: 900+ suspected cases; 220+ suspected deaths; PHEIC/PHECS.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term catalyst for MRNA from CEPI funding; expect a price move in days to weeks.</p>
  </section>
</section>


<p><i><strong>Coalition for Epidemic Preparedness Innovations</strong></i><strong> </strong><i><strong>funding builds on Moderna's prior filovirus research and supports preclinical development and Phase 1 clinical evaluation</strong></i></p> <p><strong id="dateline">CAMBRIDGE, MA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 1, 2026 / </strong>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MRNA">MRNA</a>) today announced an expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a potential vaccine against Bundibugyo ebolavirus (BDBV), a cause of Ebola virus disease for which there are currently no licensed vaccines indicated.</p><p>Under the agreement, CEPI has committed up to US $50 million to support preclinical development and Phase 1 clinical testing of Moderna's investigational BDBV vaccine candidate. The funding will also support parallel manufacturing activities, enabling doses to be produced while clinical evaluation is underway and positioning the program to rapidly advance into large-scale Phase 2/3 trials should the Phase 1 safety and immunogenicity data support further development.</p><p>The vaccine candidate is being developed using Moderna's mRNA platform, the same technology that demonstrated rapid development, scalability, and global deployment capabilities during the COVID-19 pandemic. The program also builds on Moderna's existing research and development efforts in filoviruses, including Ebola-related viruses.</p><p>The collaboration further expands Moderna's longstanding strategic collaboration with CEPI, which is focused on accelerating the development of vaccines and other countermeasures against epidemic and pandemic threats.</p><p>"At Moderna, we believe our mRNA platform can play an important role in responding rapidly to emerging infectious disease threats," said St&#233;phane Bancel, Chief Executive Officer of Moderna. "We are proud to expand our strategic collaboration with CEPI to advance a potential vaccine candidate against Bundibugyo ebolavirus, leveraging our established technology and experience in filovirus vaccine development. We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most."</p><p>By combining CEPI's funding and expertise in epidemic preparedness with Moderna's mRNA platform and manufacturing capabilities, the collaboration aims to accelerate the development of a potential vaccine that could help strengthen global readiness against future Ebola outbreaks.</p><p><strong>"</strong>With Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease," said Dr. Richard Hatchett, CEO of CEPI. "CEPI's urgent funding and support aims to advance safe, effective vaccines to help control this epidemic."</p><p>The current outbreak - declared a Public Health Emergency of International Concern (PHEIC) and a Public Health Emergency of Continental Security (PHECS) by the World Health Organization and Africa CDC, respectively - has already caused more than 900 suspected cases and more than 220 suspected deaths, making it the third largest Filovirus outbreak in history.</p><p><strong>About Moderna</strong></p><p>Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.</p><p>With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit <a rel="nofollow" href="https://pr.report/hn3n">modernatx.com</a> and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.</p><p><strong>Forward-Looking Statements</strong></p><p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's expanded collaboration with CEPI and CEPI's investment; the ability to rapidly advance into large-scale Phase 2/3 trials; the potential for a vaccine against BDBV. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at <a href="http://www.sec.gov" title="www.sec.gov">www.sec.gov</a>. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.</p><p><strong>Moderna Contacts</strong></p><p>Media:</p><p>Chris Ridley<br/>Vice President, Global Head of Communications<br/>+1 617-800-3651<br/><a rel="nofollow" href="mailto:Chris.Ridley@modernatx.com">Chris.Ridley@modernatx.com</a></p><p>Investors:</p><p>Lavina Talukdar<br/>Senior Vice President & Head of Investor Relations<br/>+1 617-209-5834<br/><a rel="nofollow" href="mailto:Lavina.Talukdar@modernatx.com">Lavina.Talukdar@modernatx.com</a></p><p><strong>SOURCE:</strong> Moderna, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/moderna-and-cepi-expand-strategic-collaboration-to-advance-potential-1172083'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1172083" width="0" height="0"/>

Moderna and CEPI expanded funding of up to $50 million to advance a Bundibugyo ebolavirus vaccine candidate using Moderna's mRNA platform, targeting preclinical and Phase 1 development with manufacturing parallelization. The collaboration aims to accelerate progression to Phase 2/3 if Phase 1 data are favorable, signaling continued government-backed support for mRNA vaccines in outbreak readiness.

Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Industry News

Related News